Lantheus (NASDAQ:LNTH) Issues FY 2025 Earnings Guidance

Lantheus (NASDAQ:LNTH) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 7.000-7.200 for the period, compared to the consensus earnings per share estimate of 6.980. The company issued revenue guidance of $1.5 billion-$1.6 billion, compared to the consensus revenue estimate of $1.6 billion.

Analysts Set New Price Targets

Several brokerages have commented on LNTH. Truist Financial reissued a “buy” rating and issued a $120.00 price objective (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. JMP Securities restated a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. The Goldman Sachs Group started coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price on the stock. Finally, StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $131.86.

Lantheus Trading Up 18.5 %

Shares of NASDAQ:LNTH traded up $14.83 during midday trading on Wednesday, hitting $94.88. The company had a trading volume of 1,962,952 shares, compared to its average volume of 860,238. Lantheus has a 12 month low of $56.44 and a 12 month high of $126.89. The stock has a market cap of $6.60 billion, a price-to-earnings ratio of 15.79 and a beta of 0.44. The firm has a fifty day simple moving average of $89.77 and a 200 day simple moving average of $96.81.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Wednesday, February 26th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Equities analysts forecast that Lantheus will post 6.01 EPS for the current fiscal year.

Insider Activity

In other news, Director James H. Thrall sold 1,000 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now owns 33,207 shares of the company’s stock, valued at $3,146,695.32. This represents a 2.92 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 1.50% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.